Subtopic Deep Dive

← Economic and Financial Impacts of Cancer

Healthcare Expenditure on Cancer Care
Research Guide

What is Healthcare Expenditure on Cancer Care?

Healthcare Expenditure on Cancer Care analyzes national and global spending patterns on cancer diagnosis, treatment, and survivorship, including trends driven by new therapies and pricing.

Studies quantify rising costs of initial cancer treatments and targeted therapies (Warren et al., 2008, 388 citations; Shih et al., 2015, 156 citations). Research examines drug pricing for anticancer drugs like ipilimumab at $120,000 per course (Howard et al., 2015, 436 citations). Systematic reviews assess cost-effectiveness of immune checkpoint inhibitors such as nivolumab and pembrolizumab (Verma et al., 2018, 310 citations). Over 20 key papers from 2008-2020 span macroeconomic modeling and therapy-specific costs.

Curated Papers

Key Challenges

Why It Matters

Expenditure analyses inform healthcare budgeting amid rising cancer incidences, as U.S. spending reached $2.7 trillion in 2011 with cancer drugs comprising 18% of national health costs (Kantarjian et al., 2013). Warren et al. (2008) show initial treatment costs increased due to more surgery and adjuvant therapy, guiding resource allocation in overburdened systems. Howard et al. (2015) reveal pricing trends for drugs extending life by months, impacting policy on affordability. Shih et al. (2015) track targeted therapy use among privately insured, highlighting drivers of nonelderly expenditure growth.

Key Research Challenges

Rising Drug Pricing Trends

Anticancer drugs like ipilimumab cost $120,000 for four months' life extension (Howard et al., 2015). Kantarjian et al. (2013) note U.S. health spending at 18% GDP fuels unsustainable prices. Modeling future escalations remains difficult amid new therapies.

Cost-Effectiveness Assessment

Verma et al. (2018) find nivolumab not cost-effective for head and neck cancers without PD-L1 cutoffs. Immune checkpoint inhibitors vary in willingness-to-pay thresholds across cancers. Limited data hinders global comparisons.

Treatment Stage Cost Variation

Sun et al. (2018) report breast cancer costs rise with stage advancement. Warren et al. (2008) link initial cost increases to more adjuvant therapies. Projections for survivorship spending challenge healthcare systems.

Essential Papers

Pricing in the Market for Anticancer Drugs

David H. Howard, Peter B. Bach, Ernst R. Berndt et al. · 2015 · The Journal of Economic Perspectives · 436 citations

In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab—brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increas...

Evaluation of Trends in the Cost of Initial Cancer Treatment

Joan L. Warren, K. Robin Yabroff, Angela Meekins et al. · 2008 · JNCI Journal of the National Cancer Institute · 388 citations

The statistically significant increase in costs of initial cancer treatment reflects more patients receiving surgery and adjuvant therapy and rising prices for these treatments. These trends are li...

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Vivek Verma, Tanja Sprave, Waqar Haque et al. · 2018 · Journal for ImmunoTherapy of Cancer · 310 citations

With limited data and from the reference WTP, nivolumab was not cost-effective for HNCs. Pembrolizumab was cost-effective for NSCLC; although not the case for nivolumab, applying PD-L1 cutoffs resu...

Mirror, Mirror 2017: International Comparison Reflects Flaws and Opportunities for Better U.S. Health Care

Michelle M. Doty Doty, David Squires Squires, Dana O. Sarnak Sarnak et al. · 2017 · 291 citations

ABSTRACTIssue: The United States health care system spends far more than other high-income countries, yet has previously documented gaps in the quality of care.Goal: This report compares health car...

Cancer Drugs in the United States: <i>Justum Pretium</i>—The Just Price

Hagop M. Kantarjian, Tito Fojo, Michael S. Mathisen et al. · 2013 · Journal of Clinical Oncology · 284 citations

In 2011, health care spending in the United States was estimated at $2.7 trillion,1 making it the sixth largest economy in the world, larger than the national budget of France. National health care...

Cancer Care Coordination: a Systematic Review and Meta-Analysis of Over 30 Years of Empirical Studies

Sherri Sheinfeld Gorin, David A. Haggstrom, Paul K. J. Han et al. · 2017 · Annals of Behavioral Medicine · 259 citations

This review offers promising findings on the impact of cancer care coordination on increasing value and reducing healthcare costs in the USA.

Cancer screening recommendations: an international comparison of high income countries

Mark H. Ebell, Thuy Nhu Thai, Kyle J. Royalty · 2018 · Public health reviews · 201 citations

Guidelines for cancer screening differ between countries, with areas of commonality but also clear differences. Recommendations have important commonalities for well-established cancer screening pr...

Reading Guide

Foundational Papers

Start with Warren et al. (2008, 388 citations) for initial treatment cost trends driven by surgery and adjuvants; then Kantarjian et al. (2013, 284 citations) on U.S. drug pricing at 18% GDP.

Recent Advances

Study Howard et al. (2015, 436 citations) for market pricing of drugs like ipilimumab; Verma et al. (2018, 310 citations) for immune inhibitor cost-effectiveness; Shih et al. (2015) for targeted therapy use.

Core Methods

Claims data analysis for cost trends (Warren et al., 2008); willingness-to-pay modeling for therapies (Verma et al., 2018); market pricing evaluations (Howard et al., 2015).

How PapersFlow Helps You Research Healthcare Expenditure on Cancer Care

Discover & Search

Research Agent uses searchPapers and citationGraph to map expenditure trends from Howard et al. (2015, 436 citations) to related pricing studies like Kantarjian et al. (2013). exaSearch uncovers global comparisons beyond U.S.-focus, while findSimilarPapers links Warren et al. (2008) initial costs to Shih et al. (2015) targeted therapies.

Analyze & Verify

Analysis Agent applies readPaperContent to extract cost data from Verma et al. (2018), then runPythonAnalysis with pandas to model cost-effectiveness trends across inhibitors. verifyResponse (CoVe) and GRADE grading verify claims like ipilimumab pricing against Howard et al. (2015), enabling statistical checks on expenditure projections.

Synthesize & Write

Synthesis Agent detects gaps in survivorship spending post-Warren et al. (2008), flagging contradictions in drug pricing (Howard et al., 2015 vs. Kantarjian et al., 2013). Writing Agent uses latexEditText, latexSyncCitations for expenditure tables, and latexCompile for reports; exportMermaid visualizes cost trend diagrams.

Use Cases

"Analyze cost trends of immune checkpoint inhibitors using Python"

Research Agent → searchPapers('immune checkpoint inhibitors cost') → Analysis Agent → readPaperContent(Verma et al. 2018) → runPythonAnalysis(pandas plot of WTP thresholds) → matplotlib cost-effectiveness graph.

"Draft LaTeX report on U.S. cancer drug pricing trends"

Synthesis Agent → gap detection(Howard et al. 2015, Kantarjian et al. 2013) → Writing Agent → latexEditText(drug pricing section) → latexSyncCitations → latexCompile → PDF with expenditure projections.

"Find code for modeling cancer expenditure forecasts"

Research Agent → paperExtractUrls(Shih et al. 2015) → paperFindGithubRepo → Code Discovery → githubRepoInspect(econometric scripts) → runPythonAnalysis(forecast trends 2001-2011 data).

Automated Workflows

Deep Research workflow conducts systematic review of 50+ expenditure papers, chaining searchPapers → citationGraph(Howard et al. 2015 hub) → structured report with GRADE scores. DeepScan applies 7-step analysis to Warren et al. (2008) costs, with CoVe checkpoints verifying surgery price rises. Theorizer generates models projecting therapy-driven spending from Verma et al. (2018) cost-effectiveness data.

Try Doxa for Healthcare Expenditure on Cancer Care Research

Frequently Asked Questions

What defines Healthcare Expenditure on Cancer Care?

It covers macroeconomic analyses of spending on cancer diagnosis, treatment, and survivorship, modeling trends from new therapies (Howard et al., 2015).

What methods quantify treatment costs?

Population-based studies track initial costs via claims data (Warren et al., 2008); systematic reviews assess cost-effectiveness with willingness-to-pay thresholds (Verma et al., 2018).

What are key papers?

Warren et al. (2008, 388 citations) on initial treatment trends; Howard et al. (2015, 436 citations) on anticancer drug pricing; Shih et al. (2015, 156 citations) on targeted therapies.

What open problems exist?

Projecting survivorship costs amid new therapies; standardizing global cost-effectiveness thresholds (Verma et al., 2018); addressing pricing unsustainability (Kantarjian et al., 2013).